In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • Now is the time to be very actively involved in your own care.

    Tony Blau, MD
    University of Washington

  • Dr. Rahib is extremely helpful and I am very thankful to have access to such professional and state-of-the-art support.

    Ines
    Daughter of pancreatic cancer patient

  • I am grateful for the concise and accurate summary of my treatment options. I have been waiting 3 years for this. Your goal to close the gap between metastatic trials and patients holds great promise to speed up success.

    Michelle Kendall
    Cancer patient

  • Cancer Commons walked with us as we faced treatment decisions following my husband’s latest recurrence of glioblastoma. Matthew’s expertise helped us sort through information during an overwhelming time. And Lauren’s concern made us feel cared for.

    Ellie
    Wife of a glioblastoma patient
  • This free-of-charge, high-quality information service is a wonderful resource for patients with advanced cancer.

    Hope S. Rugo, MD
    UCSF Comprehensive Cancer Center

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.